Dalia Rotstein, MD, MPH, St. Michael’s Hospital and the University of Toronto, Toronto, Canada, discusses the use of escalation therapy for newly diagnosed multiple sclerosis (MS) patients. An escalation approach is not appropriate for every patient, and a key step when considering the best strategy is prognostication at baseline. When a patient is diagnosed with MS, it is important to consider their prognostic factors, including demographic, clinical, and radiological features. An escalation approach should be considered when patients lack poor prognostic factors. It is also crucial to understand the patient’s preferences regarding treatment risks, route of administration, and adverse events. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.